Skip to content
DataLookout
Menu

OPITECHNCT07917546

Early COMT Inhibition in PD

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Wearable-Derived Daily OFF Time
Timeframe: Baseline and Week 4 (7 consecutive days of wearable monitoring at each time point)

Secondary (6)

Change in Step Length Variability
Change in Gait Velocity Variability
3. Change in MDS-UPDRS Part III Score
Change in WOQ-19 Score
Change in PDQ-8 Score
Show 1 moreShow less
Patient Global Impression of Change (PGI-C)

Arms and interventions

Opicapone subgroupExperimental

Participants randomized to this arm received opicapone 50 mg orally once daily as add-on therapy to their existing levodopa/dopa-decarboxylase inhibitor (DDCI) regimen for approximately four weeks. Adjustments to levodopa dosage and administration schedule were permitted during the first two weeks based on clinical response and tolerability. Treatment efficacy was evaluated through standardized clinical assessments and seven-day home-based wearable sensor monitoring at baseline and follow-up.

"L-Dopa escalation" subgroupActive comparator

Participants randomized to this arm received an additional 100-200 mg/day of levodopa combined with a dopa-decarboxylase inhibitor (DDCI) for approximately four weeks. The additional levodopa dose was administered either as an extra daily dose or distributed across existing administrations, according to the patient's treatment schedule and clinical needs. Treatment efficacy was evaluated through standardized clinical assessments and seven-day home-based wearable sensor monitoring at baseline and follow-up.

Drugs: Opicapone 50 mg, L-DOPA/DDCI

Sites

1 site in 1 country

  • Sapienza University of RomeRoma, Italy, Italy